Related Experiment Video
Updated: Jun 10, 2026

Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems
Published on: April 23, 2012
Recipients potentially infected with parvovirus B19 by red blood cell products
Michael Kai Hourfar1, Uschi Mayr-Wohlfart, Anna Themann
1Institute for Transfusion Medicine and Immunohematology, Johann Wolfgang Goethe University, German Red Cross, Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
Background:
Since 2000, blood donor screening for parvovirus B19 (B19) by nucleic acid testing (NAT) at the Ulm Institute has been conducted 6 to 8 weeks postdonation, that is, after transfusion of cellular blood products, whereas at the Frankfurt Institute all donations are screened before releasing any blood product. In this study, we evaluated the infectivity of B19-positive blood products in relation to the virus concentration in the transfused blood component.
Study Design And Methods:
Recipients were classified into two groups (A, transfused with blood products with B19 virus load less than 10(5) IU/mL; and B, transfused with blood products with B19 virus load greater than 10(5) IU/mL). Phylogenetic analyses were done for B19 DNA-positive donor and recipient pairs in the variant VP-1u genome region. All samples were investigated for immunoglobulin (Ig)M and IgG B19 antibodies.
Results:
B19 DNA was detected in 9 of 18 recipients of red blood cells (RBCs) from Group B, whereas none of the 16 recipients of RBCs from Group A were positive for B19 DNA (p=0.016). Phylogenetic analysis demonstrated identical genomic sequences between the donors and recipients. Because recipient B19 DNA and antibody results were not available before transfusion, we interpret our overall data to indicate equivocal evidence of B19 transmission by RBC transfusion.
Conclusion:
B19 transmission by cellular blood products correlates with the virus concentration and the concentration of neutralizing antibodies. Thus, blood donor screening for B19 by minipool NAT should be done to supply at-risk patients (e.g., immunosuppressed patients) with B19-negative blood components.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
11:31Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols
Published on: January 2, 2013
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cytomegalovirus Disease
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Viral Recombination
Respiratory Syncytial Virus Disease